Claims for Patent: 8,497,284

Summary for Patent: 8,497,284

Title:	C-met modulators and method of use
Abstract:	The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
Inventor(s):	Bannen; Lynne Canne (Lucerne, CA), Chan; Diva Sze-Ming (Oakland, CA), Chen; Jeff (San Francisco, CA), Dalrymple; Lisa Esther (Seattle, WA), Forsyth; Timothy Patrick (Hayward, CA), Huynh; Tai Phat (Oakland, CA), Jammalamadaka; Vasu (Pleasanton, CA), Khoury; Richard George (San Mateo, CA), Leahy; James William (San Leandro, CA), Mac; Morrison B. (San Francisco, CA), Mann; Grace (San Mateo, CA), Mann; Larry W. (Richland, MI), Nuss; John M. (Danville, CA), Parks; Jason Jevious (Sacramento, CA), Takeuchi; Craig Stacy (Burlingame, CA), Wang; Yong (Foster City, CA), Xu; Wei (Danville, CA)
Assignee:	Exelixis, Inc. (South San Francisco, CA)
Application Number:	13/249,815
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,497,284
Patent Claims:	1. A method of treating a disease or disorder, comprising administering to a mammal in need of the treatment a therapeutically effective amount of a compound having the following structure: ##STR00544## or a pharmaceutically acceptable salt thereof, or a composition containing a) a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof; and optionally b) an excipient, wherein the disease or disorder is liver cancer, gastrointestinal cancer, pancreatic cancer, bone cancer, hematologic cancer, skin cancer, kidney cancer, breast cancer, colon cancer, or fallopian tube cancer. 2. The method according to claim 1, wherein the disease or disorder is liver cancer. 3. The method according to claim 1, wherein the disease or disorder is gastrointestinal cancer. 4. The method according to claim 1, wherein the disease or disorder is pancreatic cancer. 5. The method according to claim 1, wherein the disease or disorder is bone cancer. 6. The method according to claim 1, wherein the disease or disorder is hematologic cancer. 7. The method according to claim 1, wherein the disease or disorder is skin cancer. 8. The method according to claim 1, wherein the disease or disorder is kidney cancer. 9. The method according to claim 1, wherein the disease or disorder is breast cancer. 10. The method according to claim 1, wherein the disease or disorder is colon cancer. 11. The method according to claim 1, wherein the disease or disorder is fallopian cancer. 12. The method according to claim 1, wherein the disease or disorder is liver cancer, wherein the liver cancer is hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, or hemagioma. 13. The method according to claim 1, wherein the disease or disorder is gastrointestinal cancer, wherein the gastrointestinal cancer is cancer of the esophagous which is squamous cell carcinoma, adenocarcinoma, or leiomyosarcoma; cancer of the stomach which is carcinoma, or lymphoma; cancer of the pancreas, which is ductal adenocarcinoma, insulinoma, gucagonoma, gastrinoma, carcinoid tumors, or vipoma; cancer of the small bowel, which is adenocarcinoma, lymphoma, carcinoid tumors, Karposi's sarcoma, leiomyoma, hemagioma, lipoma, or cancer of the large bowel, which is adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, or leiomyoma. 14. The method according to claim 1, wherein the disease or disorder is cancer of the pancreas, wherein the cancer of the pancreas is ductal adenocarcinoma, insulinoma, gucagonoma, gastrinoma, carcinoid tumors, or vipoma. 15. The method according to claim 1, wherein the disease or disorder is bone cancer, wherein the bone cancer is osteosarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant reticulum cell sarcoma, malignant giant cell tumor chordoma, osteocartiliginous exostoses, chondroblastoma, chondromyxofibroma, or osteoid osteoma. 16. The method according to claim 1, wherein the disease or disorder is hematologic cancer, wherein the hematologic cancer is myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, or myelodysplastic syndrome. 17. The method according to claim 1, wherein the disease or disorder is skin cancer, wherein the skin cancer is malignant melanoma, basal cell carcinoma, squamous cell carcinoma, or Karposi's sarcoma. 18. The method according to claim 1, wherein the disease or disorder is a renal tumor. 19. The method according to claim 1, wherein the disease or disorder is a breast tumor. 20. The method according to claim 1, wherein the disease or disorder is a colon cancer tumor. 21. The method according to claim 1, wherein the disease or disorder is fallopian tube carcinoma. 22. A method of treating a disease or disorder, comprising administering to a mammal in need of the treatment a therapeutically effective amount of a compound having the following structure: ##STR00545## or a pharmaceutically acceptable salt thereof, or a composition containing a) a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof; and optionally b) an excipient, wherein the disease or disorder is liver cancer, gastrointestinal cancer, pancreatic cancer, bone cancer, hematologic cancer, skin cancer, or fallopian tube cancer. 23. A method of treating a disease or disorder, comprising administering to a mammal in need of the treatment a therapeutically effective amount of a compound having the following structure: ##STR00546## or a pharmaceutically acceptable salt thereof, or a composition containing a) a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof; and optionally b) an excipient, wherein the disease or disorder is kidney cancer, breast cancer, or colon cancer.